Stocks and Investing Stocks and Investing
Fri, April 30, 2021

David Lebovitz Maintained (ALNY) at Buy with Decreased Target to $205 on, Apr 30th, 2021


Published on 2024-10-27 16:29:17 - WOPRAI, David Lebovitz
  Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $206 to $205 on, Apr 30th, 2021.

David has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Etzer Darout of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $162 on, Monday, February 22nd, 2021
  • Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Increased Target to $175 on, Friday, February 12th, 2021
  • Do Kim of "BMO Capital" Downgraded from Buy to Hold and Held Target at $185 on, Monday, January 25th, 2021


These are the ratings of the 3 analyists that currently disagree with David


  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $196 on, Friday, February 12th, 2021
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $180 on, Friday, February 12th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $235 on, Friday, February 12th, 2021

Contributing Sources